The Joint Commission (TJC) announced revisions to its suicide prevention National Patient Safety Goal on November 27. NPSG 15.01.01 now has seven elements of performance (EP), up from three and will take effect July 1, 2019.
Laureen shows you her proprietary “Bubbling and Highlighting Technique”
Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page 2018 CPC Practice Exam Answer Key 150 Questions With Full Rationale (HCPCS, ICD-9-CM, ICD-10, CPT Codes) Click here for more sample CPC practice exam questions with Full Rationale Answers Click here for more sample CPC practice exam questions and answers with full rationaleTag Archives: Revised
PICC Codes Revised for 2019
Codes for peripherally inserted central venous catheter (PICC) lines will experience a refresh in the 2019 CPT codebook. Existing codes 36568 (younger than age 5) and 36569 (age 5 and older) are revised to report PICC placement without subcutaneous port or pump, and without imaging guidance. Two new codes (one for a patient younger than age 5, […]
The post PICC Codes Revised for 2019 appeared first on AAPC Knowledge Center.
2019 Revised Codes
0362T Behavior identification supporting assessment,
each 15 minutes of technicians’ time face-to-face
with a patient, requiring the following
components: administration by the physician or
other qualified health care professional who is on
site; with the assistance of two or more
technicians; for a patient who exhibits
destructive behavior; completion in an environment
that is customized to the patient’s behavior.
0373T Adaptive behavior treatment with protocol
modification, each 15 minutes of technicians’ time
face-to-face with a patient, requiring the
following components: administration by the
physician or other qualified health care
professional who is on site; with the assistance
of two or more technicians; for a patient who
exhibits destructive behavior; completion in an
environment that is customized to the patient’s
behavior.
10021 Fine needle aspiration biopsy, without imaging
guidance; first lesion
36568 Insertion of peripherally inserted central venous
catheter (PICC), without subcutaneous port or
pump, without imaging guidance; younger than 5
years of age
36569 Insertion of peripherally inserted central venous
catheter (PICC), without subcutaneous port or
pump, without imaging guidance; age 5 years or
older
36584 Replacement, complete, of a peripherally inserted
central venous catheter (PICC), without
subcutaneous port or pump, through same venous
access, including all imaging guidance, image
documentation, and all associated radiological
supervision and interpretation required to perform
the replacement
61641 Balloon dilatation of intracranial vasospasm,
percutaneous; each additional vessel in same
vascular territory (List separately in addition to
code for primary procedure)
61642 Balloon dilatation of intracranial vasospasm,
percutaneous; each additional vessel in different
vascular territory (List separately in addition to
code for primary procedure)
74485 Dilation of ureter(s) or urethra, radiological
supervision and interpretation
77021 Magnetic resonance imaging guidance for needle
placement (eg, for biopsy, needle aspiration,
injection, or placement of localization device)
radiological supervision and interpretation
77022 Magnetic resonance imaging guidance for, and
monitoring of, parenchymal tissue ablation
77387 Guidance for localization of target volume for
delivery of radiation treatment, includes
intrafraction tracking, when performed
81162 BRCA1 (BRCA1, DNA repair associated), BRCA2
(BRCA2, DNA repair associated) (eg, hereditary
breast and ovarian cancer) gene analysis; full
sequence analysis and full duplication/deletion
analysis (ie, detection of large gene
rearrangements)
81212 BRCA1 (BRCA1, DNA repair associated), BRCA2
(BRCA2, DNA repair associated) (eg, hereditary
breast and ovarian cancer) gene analysis;
185delAG, 5385insC, 6174delT variants
81215 BRCA1 (BRCA1, DNA repair associated) (eg,
hereditary breast and ovarian cancer) gene
analysis; known familial variant
81216 BRCA2 (BRCA2, DNA repair associated) (eg,
hereditary breast and ovarian cancer) gene
analysis; full sequence analysis
81217 BRCA2 (BRCA2, DNA repair associated) (eg,
hereditary breast and ovarian cancer) gene
analysis; known familial variant
81244 FMR1 (fragile X mental retardation 1) (eg, fragile
X mental retardation) gene analysis;
characterization of alleles (eg, expanded size and
promoter methylation status)
81287 MGMT (O-6-methylguanine-DNA methyltransferase)
(eg, glioblastoma multiforme) promoter methylation
analysis
81327 SEPT9 (Septin9) (eg, colorectal cancer) promoter
methylation analysis
81400 Molecular pathology procedure, Level 1 (eg,
identification of single germline variant [eg,
SNP] by techniques such as restriction enzyme
digestion or melt curve analysis) ACADM (acyl-CoA
dehydrogenase, C-4 to C-12 straight chain, MCAD)
(eg, medium chain acyl dehydrogenase deficiency),
K304E variant ACE (angiotensin converting enzyme)
(eg, hereditary blood pressure regulation),
insertion/deletion variant AGTR1 (angiotensin II
receptor, type 1) (eg, essential hypertension),
1166A>C variant BCKDHA (branched chain keto acid
dehydrogenase E1, alpha polypeptide) (eg, maple
syrup urine disease, type 1A), Y438N variant CCR5
(chemokine C-C motif receptor 5) (eg, HIV
resistance), 32-bp deletion mutation/794 825del32
deletion CLRN1 (clarin 1) (eg, Usher syndrome,
type 3), N48K variant F2 (coagulation factor 2)
(eg, hereditary hypercoagulability), 1199G>A
variant F5 (coagulation factor V) (eg, hereditary
hypercoagulability), HR2 variant F7 (coagulation
factor VII [serum prothrombin conversion
accelerator]) (eg, hereditary hypercoagulability),
R353Q variant F13B (coagulation factor XIII, B
polypeptide) (eg, hereditary hypercoagulability),
V34L variant FGB (fibrinogen beta chain) (eg,
hereditary ischemic heart disease), -455G>A
variant FGFR1 (fibroblast growth factor receptor
1) (eg, Pfeiffer syndrome type 1,
craniosynostosis), P252R variant FGFR3 (fibroblast
growth factor receptor 3) (eg, Muenke syndrome),
P250R variant FKTN (fukutin) (eg, Fukuyama
congenital muscular dystrophy), retrotransposon
insertion variant GNE (glucosamine
[UDP-N-acetyl]-2-epimerase/N-acetylmannosamine
kinase) (eg, inclusion body myopathy 2 [IBM2],
Nonaka myopathy), M712T variant IVD
(isovaleryl-CoA dehydrogenase) (eg, isovaleric
acidemia), A282V variant LCT (lactase-phlorizin
hydrolase) (eg, lactose intolerance), 13910 C>T
variant NEB (nebulin) (eg, nemaline myopathy 2),
exon 55 deletion variant PCDH15
(protocadherin-related 15) (eg, Usher syndrome
type 1F), R245X variant SERPINE1 (serpine
peptidase inhibitor clade E, member 1, plasminogen
activator inhibitor -1, PAI-1) (eg,
thrombophilia), 4G variant SHOC2 (soc-2 suppressor
of clear homolog) (eg, Noonan-like syndrome with
loose anagen hair), S2G variant SRY (sex
determining region Y) (eg, 46,XX testicular
disorder of sex development, gonadal dysgenesis),
gene analysis TOR1A (torsin family 1, member A
[torsin A]) (eg, early-onset primary dystonia
[DYT1]), 907_909delGAG (904_906delGAG) variant
81401 Molecular pathology procedure, Level 2 (eg, 2-10
SNPs, 1 methylated variant, or 1 somatic variant
[typically using nonsequencing target variant
analysis], or detection of a dynamic mutation
disorder/triplet repeat) ABCC8 (ATP-binding
cassette, sub-family C [CFTR/MRP], member 8) (eg,
familial hyperinsulinism), common variants (eg,
c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL
proto-oncogene 1, non-receptor tyrosine kinase)
(eg, acquired imatinib resistance), T315I variant
ACADM (acyl-CoA dehydrogenase, C-4 to C-12
straight chain, MCAD) (eg, medium chain acyl
dehydrogenase deficiency), commons variants (eg,
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor
surface) (eg, drug metabolism), common variants
(eg, G16R, Q27E) APOB (apolipoprotein B) (eg,
familial hypercholesterolemia type B), common
variants (eg, R3500Q, R3500W) APOE (apolipoprotein
E) (eg, hyperlipoproteinemia type III,
cardiovascular disease, Alzheimer disease), common
variants (eg, *2, *3, *4) CBFB/MYH11 (inv(16))
(eg, acute myeloid leukemia), qualitative, and
quantitative, if performed CBS
(cystathionine-beta-synthase) (eg, homocystinuria,
cystathionine beta-synthase deficiency), common
variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,
t(11;14)) (eg, mantle cell lymphoma) translocation
analysis, major breakpoint, qualitative, and
quantitative, if performed CFH/ARMS2 (complement
factor H/age-related maculopathy susceptibility 2)
(eg, macular degeneration), common variants (eg,
Y402H [CFH], A69S [ARMS2]) DEK/NUP214 (t(6;9))
(eg, acute myeloid leukemia), translocation
analysis, qualitative, and quantitative, if
performed E2A/PBX1 (t(1;19)) (eg, acute
lymphocytic leukemia), translocation analysis,
qualitative, and quantitative, if performed
EML4/ALK (inv(2)) (eg, non-small cell lung
cancer), translocation or inversion analysis
ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile
fibrosarcoma), translocation analysis,
qualitative, and quantitative, if performed
ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic
leukemia), translocation analysis, qualitative,
and quantitative, if performed EWSR1/ATF1
(t(12;22)) (eg, clear cell sarcoma), translocation
analysis, qualitative, and quantitative, if
performed EWSR1/ERG (t(21;22)) (eg, Ewing
sarcoma/peripheral neuroectodermal tumor),
translocation analysis, qualitative, and
quantitative, if performed EWSR1/FLI1 (t(11;22))
(eg, Ewing sarcoma/peripheral neuroectodermal
tumor), translocation analysis, qualitative, and
quantitative, if performed EWSR1/WT1 (t(11;22))
(eg, desmoplastic small round cell tumor),
translocation analysis, qualitative, and
quantitative, if performed F11 (coagulation factor
XI) (eg, coagulation disorder), common variants
(eg, E117X [Type II], F283L [Type III],
IVS14del14, and IVS14+1G>A [Type I]) FGFR3
(fibroblast growth factor receptor 3) (eg,
achondroplasia, hypochondroplasia), common
variants (eg, 1138G>A, 1138G>C, 1620C>A, 1620C>G)
FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive
chronic eosinophilic leukemia), qualitative, and
quantitative, if performed FLG (filaggrin) (eg,
ichthyosis vulgaris), common variants (eg, R501X,
2282del4, R2447X, S3247X, 3702delG) FOXO1/PAX3
(t(2;13)) (eg, alveolar rhabdomyosarcoma),
translocation analysis, qualitative, and
quantitative, if performed FOXO1/PAX7 (t(1;13))
(eg, alveolar rhabdomyosarcoma), translocation
analysis, qualitative, and quantitative, if
performed FUS/DDIT3 (t(12;16)) (eg, myxoid
liposarcoma), translocation analysis, qualitative,
and quantitative, if performed GALC
(galactosylceramidase) (eg, Krabbe disease),
common variants (eg, c.857G>A, 30-kb deletion)
GALT (galactose-1-phosphate uridylyltransferase)
(eg, galactosemia), common variants (eg, Q188R,
S135L, K285N, T138M, L195P, Y209C, IVS2-2A>G,
P171S, del5kb, N314D, L218L/N314D) H19 (imprinted
maternally expressed transcript [non-protein
coding]) (eg, Beckwith-Wiedemann syndrome),
methylation analysis IGH@/BCL2 (t(14;18)) (eg,
follicular lymphoma), translocation analysis;
single breakpoint (eg, major breakpoint region
[MBR] or minor cluster region [mcr]), qualitative
or quantitative (When both MBR and mcr breakpoints
are performed, use 81402) KCNQ1OT1 (KCNQ1
overlapping transcript 1 [non-protein coding])
(eg, Beckwith-Wiedemann syndrome), methylation
analysis LINC00518 (long intergenic non-protein
coding RNA 518) (eg, melanoma), expression
analysis LRRK2 (leucine-rich repeat kinase 2) (eg,
Parkinson disease), common variants (eg, R1441G,
G2019S, I2020T) MED12 (mediator complex subunit
12) (eg, FG syndrome type 1, Lujan syndrome),
common variants (eg, R961W, N1007S) MEG3/DLK1
(maternally expressed 3 [non-protein
coding]/delta-like 1 homolog [Drosophila]) (eg,
intrauterine growth retardation), methylation
analysis MLL/AFF1 (t(4;11)) (eg, acute
lymphoblastic leukemia), translocation analysis,
qualitative, and quantitative, if performed
MLL/MLLT3 (t(9;11)) (eg, acute myeloid leukemia),
translocation analysis, qualitative, and
quantitative, if performed MT-ATP6
(mitochondrially encoded ATP synthase 6) (eg,
neuropathy with ataxia and retinitis pigmentosa
[NARP], Leigh syndrome), common variants (eg,
m.8993T>G, m.8993T>C) MT-ND4, MT-ND6
(mitochondrially encoded NADH dehydrogenase 4,
mitochondrially encoded NADH dehydrogenase 6) (eg,
Leber hereditary optic neuropathy [LHON]), common
variants (eg, m.11778G>A, m.3460G>A, m.14484T>C)
MT-ND5 (mitochondrially encoded tRNA leucine 1
[UUA/G], mitochondrially encoded NADH
dehydrogenase 5) (eg, mitochondrial encephalopathy
with lactic acidosis and stroke-like episodes
[MELAS]), common variants (eg, m.3243A>G,
m.3271T>C, m.3252A>G, m.13513G>A) MT-RNR1
(mitochondrially encoded 12S RNA) (eg,
nonsyndromic hearing loss), common variants (eg,
m.1555A>G, m.1494C>T) MT-TK (mitochondrially
encoded tRNA lysine) (eg, myoclonic epilepsy with
ragged-red fibers [MERRF]), common variants (eg,
m.8344A>G, m.8356T>C) MT-TL1 (mitochondrially
encoded tRNA leucine 1 [UUA/G]) (eg, diabetes and
hearing loss), common variants (eg, m.3243A>G,
m.14709 T>C) MT-TL1 MT-TS1, MT-RNR1
(mitochondrially encoded tRNA serine 1 [UCN],
mitochondrially encoded 12S RNA) (eg, nonsyndromic
sensorineural deafness [including
aminoglycoside-induced nonsyndromic deafness]),
common variants (eg, m.7445A>G, m.1555A>G) MUTYH
(mutY homolog [E. coli]) (eg, MYH-associated
polyposis), common variants (eg, Y165C, G382D)
NOD2 (nucleotide-binding oligomerization domain
containing 2) (eg, Crohn’s disease, Blau
syndrome), common variants (eg, SNP 8, SNP 12, SNP
13) NPM1/ALK (t(2;5)) (eg, anaplastic large cell
lymphoma), translocation analysis PAX8/PPARG
(t(2;3) (q13;p25)) (eg, follicular thyroid
carcinoma), translocation analysis PRAME
(preferentially expressed antigen in melanoma)
(eg, melanoma), expression analysis PRSS1
(protease, serine, 1 [trypsin 1]) (eg, hereditary
pancreatitis), common variants (eg, N29I, A16V,
R122H) PYGM (phosphorylase, glycogen, muscle) (eg,
glycogen storage disease type V, McArdle disease),
common variants (eg, R50X, G205S) RUNX1/RUNX1T1
(t(8;21)) (eg, acute myeloid leukemia)
translocation analysis, qualitative, and
quantitative, if performed SS18/SSX1 (t(X;18))
(eg, synovial sarcoma), translocation analysis,
qualitative, and quantitative, if performed
SS18/SSX2 (t(X;18)) (eg, synovial sarcoma),
translocation analysis, qualitative, and
quantitative, if performed VWF (von Willebrand
factor) (eg, von Willebrand disease type 2N),
common variants (eg, T791M, R816W, R854Q)
81403 Molecular pathology procedure, Level 4 (eg,
analysis of single exon by DNA sequence analysis,
analysis of >10 amplicons using multiplex PCR in 2
or more independent reactions, mutation scanning
or duplication/deletion variants of 2-5 exons) ANG
(angiogenin, ribonuclease, RNase A family, 5) (eg,
amyotrophic lateral sclerosis), full gene sequence
ARX (aristaless-related homeobox) (eg, X-linked
lissencephaly with ambiguous genitalia, X-linked
mental retardation), duplication/deletion analysis
CEL (carboxyl ester lipase [bile salt-stimulated
lipase]) (eg, maturity-onset diabetes of the young
[MODY]), targeted sequence analysis of exon 11
(eg, c.1785delC, c.1686delT) CTNNB1 (catenin
[cadherin-associated protein], beta 1, 88kDa) (eg,
desmoid tumors), targeted sequence analysis (eg,
exon 3) DAZ/SRY (deleted in azoospermia and sex
determining region Y) (eg, male infertility),
common deletions (eg, AZFa, AZFb, AZFc, AZFd)
DNMT3A (DNA [cytosine-5-]-methyltransferase 3
alpha) (eg, acute myeloid leukemia), targeted
sequence analysis (eg, exon 23) EPCAM (epithelial
cell adhesion molecule) (eg, Lynch syndrome),
duplication/deletion analysis F8 (coagulation
factor VIII) (eg, hemophilia A), inversion
analysis, intron 1 and intron 22A F12 (coagulation
factor XII [Hageman factor]) (eg, angioedema,
hereditary, type III; factor XII deficiency),
targeted sequence analysis of exon 9 FGFR3
(fibroblast growth factor receptor 3) (eg,
isolated craniosynostosis), targeted sequence
analysis (eg, exon 7) (For targeted sequence
analysis of multiple FGFR3 exons, use 81404) GJB1
(gap junction protein, beta 1) (eg,
Charcot-Marie-Tooth X-linked), full gene sequence
GNAQ (guanine nucleotide-binding protein G[q]
subunit alpha) (eg, uveal melanoma), common
variants (eg, R183, Q209) Human erythrocyte
antigen gene analyses (eg, SLC14A1 [Kidd blood
group], BCAM [Lutheran blood group], ICAM4
[Landsteiner-Wiener blood group], SLC4A1 [Diego
blood group], AQP1 [Colton blood group], ERMAP
[Scianna blood group], RHCE [Rh blood group, CcEe
antigens], KEL [Kell blood group], DARC [Duffy
blood group], GYPA, GYPB, GYPE [MNS blood group],
ART4 [Dombrock blood group]) (eg, sickle-cell
disease, thalassemia, hemolytic transfusion
reactions, hemolytic disease of the fetus or
newborn), common variants HRAS (v-Ha-ras Harvey
rat sarcoma viral oncogene homolog) (eg, Costello
syndrome), exon 2 sequence JAK2 (Janus kinase 2)
(eg, myeloproliferative disorder), exon 12
sequence and exon 13 sequence, if performed KCNC3
(potassium voltage-gated channel, Shaw-related
subfamily, member 3) (eg, spinocerebellar ataxia),
targeted sequence analysis (eg, exon 2) KCNJ2
(potassium inwardly-rectifying channel, subfamily
J, member 2) (eg, Andersen-Tawil syndrome), full
gene sequence KCNJ11 (potassium
inwardly-rectifying channel, subfamily J, member
11) (eg, familial hyperinsulinism), full gene
sequence Killer cell immunoglobulin-like receptor
(KIR) gene family (eg, hematopoietic stem cell
transplantation), genotyping of KIR family genes
Known familial variant not otherwise specified,
for gene listed in Tier 1 or Tier 2, or identified
during a genomic sequencing procedure, DNA
sequence analysis, each variant exon (For a known
familial variant that is considered a common
variant, use specific common variant Tier 1 or
Tier 2 code) MC4R (melanocortin 4 receptor) (eg,
obesity), full gene sequence MICA (MHC class I
polypeptide-related sequence A) (eg, solid organ
transplantation), common variants (eg, *001, *002)
MPL (myeloproliferative leukemia virus oncogene,
thrombopoietin receptor, TPOR) (eg,
myeloproliferative disorder), exon 10 sequence
MT-RNR1 (mitochondrially encoded 12S RNA) (eg,
nonsyndromic hearing loss), full gene sequence
MT-TS1 (mitochondrially encoded tRNA serine 1)
(eg, nonsyndromic hearing loss), full gene
sequence NDP (Norrie disease [pseudoglioma]) (eg,
Norrie disease), duplication/deletion analysis
NHLRC1 (NHL repeat containing 1) (eg, progressive
myoclonus epilepsy), full gene sequence PHOX2B
(paired-like homeobox 2b) (eg, congenital central
hypoventilation syndrome), duplication/deletion
analysis PLN (phospholamban) (eg, dilated
cardiomyopathy, hypertrophic cardiomyopathy), full
gene sequence RHD (Rh blood group, D antigen) (eg,
hemolytic disease of the fetus and newborn, Rh
maternal/fetal compatibility), deletion analysis
(eg, exons 4, 5, and 7, pseudogene) RHD (Rh blood
group, D antigen) (eg, hemolytic disease of the
fetus and newborn, Rh maternal/fetal
compatibility), deletion analysis (eg, exons 4, 5,
and 7, pseudogene), performed on cell-free fetal
DNA in maternal blood (For human erythrocyte gene
analysis of RHD, use a separate unit of 81403)
SH2D1A (SH2 domain containing 1A) (eg, X-linked
lymphoproliferative syndrome),
duplication/deletion analysis TWIST1 (twist
homolog 1 [Drosophila]) (eg, Saethre-Chotzen
syndrome), duplication/deletion analysis UBA1
(ubiquitin-like modifier activating enzyme 1) (eg,
spinal muscular atrophy, X-linked), targeted
sequence analysis (eg, exon 15) VHL (von
Hippel-Lindau tumor suppressor) (eg, von
Hippel-Lindau familial cancer syndrome),
deletion/duplication analysis VWF (von Willebrand
factor) (eg, von Willebrand disease types 2A, 2B,
2M), targeted sequence analysis (eg, exon 28)
81404 Molecular pathology procedure, Level 5 (eg,
analysis of 2-5 exons by DNA sequence analysis,
mutation scanning or duplication/deletion variants
of 6-10 exons, or characterization of a dynamic
mutation disorder/triplet repeat by Southern blot
analysis) ACADS (acyl-CoA dehydrogenase, C-2 to
C-3 short chain) (eg, short chain acyl-CoA
dehydrogenase deficiency), targeted sequence
analysis (eg, exons 5 and 6) AQP2 (aquaporin 2
[collecting duct]) (eg, nephrogenic diabetes
insipidus), full gene sequence ARX (aristaless
related homeobox) (eg, X-linked lissencephaly with
ambiguous genitalia, X-linked mental retardation),
full gene sequence AVPR2 (arginine vasopressin
receptor 2) (eg, nephrogenic diabetes insipidus),
full gene sequence BBS10 (Bardet-Biedl syndrome
10) (eg, Bardet-Biedl syndrome), full gene
sequence BTD (biotinidase) (eg, biotinidase
deficiency), full gene sequence C10orf2
(chromosome 10 open reading frame 2) (eg,
mitochondrial DNA depletion syndrome), full gene
sequence CAV3 (caveolin 3) (eg, CAV3-related
distal myopathy, limb-girdle muscular dystrophy
type 1C), full gene sequence CD40LG (CD40 ligand)
(eg, X-linked hyper IgM syndrome), full gene
sequence CDKN2A (cyclin-dependent kinase inhibitor
2A) (eg, CDKN2A-related cutaneous malignant
melanoma, familial atypical mole-malignant
melanoma syndrome), full gene sequence CLRN1
(clarin 1) (eg, Usher syndrome, type 3), full gene
sequence COX6B1 (cytochrome c oxidase subunit VIb
polypeptide 1) (eg, mitochondrial respiratory
chain complex IV deficiency), full gene sequence
CPT2 (carnitine palmitoyltransferase 2) (eg,
carnitine palmitoyltransferase II deficiency),
full gene sequence CRX (cone-rod homeobox) (eg,
cone-rod dystrophy 2, Leber congenital amaurosis),
full gene sequence CYP1B1 (cytochrome P450, family
1, subfamily B, polypeptide 1) (eg, primary
congenital glaucoma), full gene sequence EGR2
(early growth response 2) (eg,
Charcot-Marie-Tooth), full gene sequence EMD
(emerin) (eg, Emery-Dreifuss muscular dystrophy),
duplication/deletion analysis EPM2A (epilepsy,
progressive myoclonus type 2A, Lafora disease
[laforin]) (eg, progressive myoclonus epilepsy),
full gene sequence FGF23 (fibroblast growth factor
23) (eg, hypophosphatemic rickets), full gene
sequence FGFR2 (fibroblast growth factor receptor
2) (eg, craniosynostosis, Apert syndrome, Crouzon
syndrome), targeted sequence analysis (eg, exons
8, 10) FGFR3 (fibroblast growth factor receptor 3)
(eg, achondroplasia, hypochondroplasia), targeted
sequence analysis (eg, exons 8, 11, 12, 13) FHL1
(four and a half LIM domains 1) (eg,
Emery-Dreifuss muscular dystrophy), full gene
sequence FKRP (fukutin related protein) (eg,
congenital muscular dystrophy type 1C [MDC1C],
limb-girdle muscular dystrophy [LGMD] type 2I),
full gene sequence FOXG1 (forkhead box G1) (eg,
Rett syndrome), full gene sequence FSHMD1A
(facioscapulohumeral muscular dystrophy 1A) (eg,
facioscapulohumeral muscular dystrophy),
evaluation to detect abnormal (eg, deleted)
alleles FSHMD1A (facioscapulohumeral muscular
dystrophy 1A) (eg, facioscapulohumeral muscular
dystrophy), characterization of haplotype(s) (ie,
chromosome 4A and 4B haplotypes) GH1 (growth
hormone 1) (eg, growth hormone deficiency), full
gene sequence GP1BB (glycoprotein Ib [platelet],
beta polypeptide) (eg, Bernard-Soulier syndrome
type B), full gene sequence (For common deletion
variants of alpha globin 1 and alpha globin 2
genes, use 81257) HNF1B (HNF1 homeobox B) (eg,
maturity-onset diabetes of the young [MODY]),
duplication/deletion analysis HRAS (v-Ha-ras
Harvey rat sarcoma viral oncogene homolog) (eg,
Costello syndrome), full gene sequence HSD3B2
(hydroxy-delta-5-steroid dehydrogenase, 3 beta-
and steroid delta-isomerase 2) (eg,
3-beta-hydroxysteroid dehydrogenase type II
deficiency), full gene sequence HSD11B2
(hydroxysteroid [11-beta] dehydrogenase 2) (eg,
mineralocorticoid excess syndrome), full gene
sequence HSPB1 (heat shock 27kDa protein 1) (eg,
Charcot-Marie-Tooth disease), full gene sequence
INS (insulin) (eg, diabetes mellitus), full gene
sequence KCNJ1 (potassium inwardly-rectifying
channel, subfamily J, member 1) (eg, Bartter
syndrome), full gene sequence KCNJ10 (potassium
inwardly-rectifying channel, subfamily J, member
10) (eg, SeSAME syndrome, EAST syndrome,
sensorineural hearing loss), full gene sequence
LITAF (lipopolysaccharide-induced TNF factor) (eg,
Charcot-Marie-Tooth), full gene sequence MEFV
(Mediterranean fever) (eg, familial Mediterranean
fever), full gene sequence MEN1 (multiple
endocrine neoplasia I) (eg, multiple endocrine
neoplasia type 1, Wermer syndrome),
duplication/deletion analysis MMACHC
(methylmalonic aciduria [cobalamin deficiency]
cblC type, with homocystinuria) (eg, methylmalonic
acidemia and homocystinuria), full gene sequence
MPV17 (MpV17 mitochondrial inner membrane protein)
(eg, mitochondrial DNA depletion syndrome),
duplication/deletion analysis NDP (Norrie disease
[pseudoglioma]) (eg, Norrie disease), full gene
sequence NDUFA1 (NADH dehydrogenase [ubiquinone] 1
alpha subcomplex, 1, 7.5kDa) (eg, Leigh syndrome,
mitochondrial complex I deficiency), full gene
sequence NDUFAF2 (NADH dehydrogenase [ubiquinone]
1 alpha subcomplex, assembly factor 2) (eg, Leigh
syndrome, mitochondrial complex I deficiency),
full gene sequence NDUFS4 (NADH dehydrogenase
[ubiquinone] Fe-S protein 4, 18kDa [NADH-coenzyme
Q reductase]) (eg, Leigh syndrome, mitochondrial
complex I deficiency), full gene sequence NIPA1
(non-imprinted in Prader-Willi/Angelman syndrome
1) (eg, spastic paraplegia), full gene sequence
NLGN4X (neuroligin 4, X-linked) (eg, autism
spectrum disorders), duplication/deletion analysis
NPC2 (Niemann-Pick disease, type C2 [epididymal
secretory protein E1]) (eg, Niemann-Pick disease
type C2), full gene sequence NR0B1 (nuclear
receptor subfamily 0, group B, member 1) (eg,
congenital adrenal hypoplasia), full gene sequence
PDX1 (pancreatic and duodenal homeobox 1) (eg,
maturity-onset diabetes of the young [MODY]), full
gene sequence PHOX2B (paired-like homeobox 2b)
(eg, congenital central hypoventilation syndrome),
full gene sequence PIK3CA
(phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha) (eg, colorectal cancer),
targeted sequence analysis (eg, exons 9 and 20)
PLP1 (proteolipid protein 1) (eg,
Pelizaeus-Merzbacher disease, spastic paraplegia),
duplication/deletion analysis PQBP1 (polyglutamine
binding protein 1) (eg, Renpenning syndrome),
duplication/deletion analysis PRNP (prion protein)
(eg, genetic prion disease), full gene sequence
PROP1 (PROP paired-like homeobox 1) (eg, combined
pituitary hormone deficiency), full gene sequence
PRPH2 (peripherin 2 [retinal degeneration, slow])
(eg, retinitis pigmentosa), full gene sequence
PRSS1 (protease, serine, 1 [trypsin 1]) (eg,
hereditary pancreatitis), full gene sequence RAF1
(v-raf-1 murine leukemia viral oncogene homolog 1)
(eg, LEOPARD syndrome), targeted sequence analysis
(eg, exons 7, 12, 14, 17) RET (ret proto-oncogene)
(eg, multiple endocrine neoplasia, type 2B and
familial medullary thyroid carcinoma), common
variants (eg, M918T, 2647_2648delinsTT, A883F) RHO
(rhodopsin) (eg, retinitis pigmentosa), full gene
sequence RP1 (retinitis pigmentosa 1) (eg,
retinitis pigmentosa), full gene sequence SCN1B
(sodium channel, voltage-gated, type I, beta) (eg,
Brugada syndrome), full gene sequence SCO2 (SCO
cytochrome oxidase deficient homolog 2 [SCO1L])
(eg, mitochondrial respiratory chain complex IV
deficiency), full gene sequence SDHC (succinate
dehydrogenase complex, subunit C, integral
membrane protein, 15kDa) (eg, hereditary
paraganglioma-pheochromocytoma syndrome),
duplication/deletion analysis SDHD (succinate
dehydrogenase complex, subunit D, integral
membrane protein) (eg, hereditary paraganglioma),
full gene sequence SGCG (sarcoglycan, gamma [35kDa
dystrophin-associated glycoprotein]) (eg,
limb-girdle muscular dystrophy),
duplication/deletion analysis SH2D1A (SH2 domain
containing 1A) (eg, X-linked lymphoproliferative
syndrome), full gene sequence SLC16A2 (solute
carrier family 16, member 2 [thyroid hormone
transporter]) (eg, specific thyroid hormone cell
transporter deficiency, Allan-Herndon-Dudley
syndrome), duplication/deletion analysis SLC25A20
(solute carrier family 25 [carnitine/acylcarnitine
translocase], member 20) (eg,
carnitine-acylcarnitine translocase deficiency),
duplication/deletion analysis SLC25A4 (solute
carrier family 25 [mitochondrial carrier; adenine
nucleotide translocator], member 4) (eg,
progressive external ophthalmoplegia), full gene
sequence SOD1 (superoxide dismutase 1, soluble)
(eg, amyotrophic lateral sclerosis), full gene
sequence SPINK1 (serine peptidase inhibitor, Kazal
type 1) (eg, hereditary pancreatitis), full gene
sequence STK11 (serine/threonine kinase 11) (eg,
Peutz-Jeghers syndrome), duplication/deletion
analysis TACO1 (translational activator of
mitochondrial encoded cytochrome c oxidase I) (eg,
mitochondrial respiratory chain complex IV
deficiency), full gene sequence THAP1 (THAP domain
containing, apoptosis associated protein 1) (eg,
torsion dystonia), full gene sequence TOR1A
(torsin family 1, member A [torsin A]) (eg,
torsion dystonia), full gene sequence TP53 (tumor
protein 53) (eg, tumor samples), targeted sequence
analysis of 2-5 exons TTPA (tocopherol [alpha]
transfer protein) (eg, ataxia), full gene sequence
TTR (transthyretin) (eg, familial transthyretin
amyloidosis), full gene sequence TWIST1 (twist
homolog 1 [Drosophila]) (eg, Saethre-Chotzen
syndrome), full gene sequence TYR (tyrosinase
[oculocutaneous albinism IA]) (eg, oculocutaneous
albinism IA), full gene sequence USH1G (Usher
syndrome 1G [autosomal recessive]) (eg, Usher
syndrome, type 1), full gene sequence VHL (von
Hippel-Lindau tumor suppressor) (eg, von
Hippel-Lindau familial cancer syndrome), full gene
sequence VWF (von Willebrand factor) (eg, von
Willebrand disease type 1C), targeted sequence
analysis (eg, exons 26, 27, 37) ZEB2 (zinc finger
E-box binding homeobox 2) (eg, Mowat-Wilson
syndrome), duplication/deletion analysis ZNF41
(zinc finger protein 41) (eg, X-linked mental
retardation 89), full gene sequence
81405 Molecular pathology procedure, Level 6 (eg,
analysis of 6-10 exons by DNA sequence analysis,
mutation scanning or duplication/deletion variants
of 11-25 exons, regionally targeted cytogenomic
array analysis) ABCD1 (ATP-binding cassette,
sub-family D [ALD], member 1) (eg,
adrenoleukodystrophy), full gene sequence ACADS
(acyl-CoA dehydrogenase, C-2 to C-3 short chain)
(eg, short chain acyl-CoA dehydrogenase
deficiency), full gene sequence ACTA2 (actin,
alpha 2, smooth muscle, aorta) (eg, thoracic
aortic aneurysms and aortic dissections), full
gene sequence ACTC1 (actin, alpha, cardiac muscle
1) (eg, familial hypertrophic cardiomyopathy),
full gene sequence ANKRD1 (ankyrin repeat domain
1) (eg, dilated cardiomyopathy), full gene
sequence APTX (aprataxin) (eg, ataxia with
oculomotor apraxia 1), full gene sequence ARSA
(arylsulfatase A) (eg, arylsulfatase A
deficiency), full gene sequence BCKDHA (branched
chain keto acid dehydrogenase E1, alpha
polypeptide) (eg, maple syrup urine disease, type
1A), full gene sequence BCS1L (BCS1-like [S.
cerevisiae]) (eg, Leigh syndrome, mitochondrial
complex III deficiency, GRACILE syndrome), full
gene sequence BMPR2 (bone morphogenetic protein
receptor, type II [serine/threonine kinase]) (eg,
heritable pulmonary arterial hypertension),
duplication/deletion analysis CASQ2 (calsequestrin
2 [cardiac muscle]) (eg, catecholaminergic
polymorphic ventricular tachycardia), full gene
sequence CASR (calcium-sensing receptor) (eg,
hypocalcemia), full gene sequence CDKL5
(cyclin-dependent kinase-like 5) (eg, early
infantile epileptic encephalopathy),
duplication/deletion analysis CHRNA4 (cholinergic
receptor, nicotinic, alpha 4) (eg, nocturnal
frontal lobe epilepsy), full gene sequence CHRNB2
(cholinergic receptor, nicotinic, beta 2
[neuronal]) (eg, nocturnal frontal lobe epilepsy),
full gene sequence COX10 (COX10 homolog,
cytochrome c oxidase assembly protein) (eg,
mitochondrial respiratory chain complex IV
deficiency), full gene sequence COX15 (COX15
homolog, cytochrome c oxidase assembly protein)
(eg, mitochondrial respiratory chain complex IV
deficiency), full gene sequence CPOX
(coproporphyrinogen oxidase) (eg, hereditary
coproporphyria), full gene sequence CTRC
(chymotrypsin C) (eg, hereditary pancreatitis),
full gene sequence CYP11B1 (cytochrome P450,
family 11, subfamily B, polypeptide 1) (eg,
congenital adrenal hyperplasia), full gene
sequence CYP17A1 (cytochrome P450, family 17,
subfamily A, polypeptide 1) (eg, congenital
adrenal hyperplasia), full gene sequence CYP21A2
(cytochrome P450, family 21, subfamily A,
polypeptide2) (eg, steroid 21-hydroxylase isoform,
congenital adrenal hyperplasia), full gene
sequence Cytogenomic constitutional targeted
microarray analysis of chromosome 22q13 by
interrogation of genomic regions for copy number
and single nucleotide polymorphism (SNP) variants
for chromosomal abnormalities (When performing
genome-wide cytogenomic constitutional microarray
analysis, see 81228, 81229) (Do not report
analyte-specific molecular pathology procedures
separately when the specific analytes are included
as part of the microarray analysis of chromosome
22q13) (Do not report 88271 when performing
cytogenomic microarray analysis) DBT
(dihydrolipoamide branched chain transacylase E2)
(eg, maple syrup urine disease, type 2),
duplication/deletion analysis DCX (doublecortin)
(eg, X-linked lissencephaly), full gene sequence
DES (desmin) (eg, myofibrillar myopathy), full
gene sequence DFNB59 (deafness, autosomal
recessive 59) (eg, autosomal recessive
nonsyndromic hearing impairment), full gene
sequence DGUOK (deoxyguanosine kinase) (eg,
hepatocerebral mitochondrial DNA depletion
syndrome), full gene sequence DHCR7
(7-dehydrocholesterol reductase) (eg,
Smith-Lemli-Opitz syndrome), full gene sequence
EIF2B2 (eukaryotic translation initiation factor
2B, subunit 2 beta, 39kDa) (eg,
leukoencephalopathy with vanishing white matter),
full gene sequence EMD (emerin) (eg,
Emery-Dreifuss muscular dystrophy), full gene
sequence ENG (endoglin) (eg, hereditary
hemorrhagic telangiectasia, type 1),
duplication/deletion analysis EYA1 (eyes absent
homolog 1 [Drosophila]) (eg, branchio-oto-renal
[BOR] spectrum disorders), duplication/deletion
analysis FGFR1 (fibroblast growth factor receptor
1) (eg, Kallmann syndrome 2), full gene sequence
FH (fumarate hydratase) (eg, fumarate hydratase
deficiency, hereditary leiomyomatosis with renal
cell cancer), full gene sequence FKTN (fukutin)
(eg, limb-girdle muscular dystrophy [LGMD] type 2M
or 2L), full gene sequence FTSJ1 (FtsJ RNA
methyltransferase homolog 1 [E. coli]) (eg,
X-linked mental retardation 9),
duplication/deletion analysis GABRG2
(gamma-aminobutyric acid [GABA] A receptor, gamma
2) (eg, generalized epilepsy with febrile
seizures), full gene sequence GCH1 (GTP
cyclohydrolase 1) (eg, autosomal dominant
dopa-responsive dystonia), full gene sequence
GDAP1 (ganglioside-induced
differentiation-associated protein 1) (eg,
Charcot-Marie-Tooth disease), full gene sequence
GFAP (glial fibrillary acidic protein) (eg,
Alexander disease), full gene sequence GHR (growth
hormone receptor) (eg, Laron syndrome), full gene
sequence GHRHR (growth hormone releasing hormone
receptor) (eg, growth hormone deficiency), full
gene sequence GLA (galactosidase, alpha) (eg,
Fabry disease), full gene sequence HNF1A (HNF1
homeobox A) (eg, maturity-onset diabetes of the
young [MODY]), full gene sequence HNF1B (HNF1
homeobox B) (eg, maturity-onset diabetes of the
young [MODY]), full gene sequence HTRA1 (HtrA
serine peptidase 1) (eg, macular degeneration),
full gene sequence IDS (iduronate 2-sulfatase)
(eg, mucopolysacchridosis, type II), full gene
sequence IL2RG (interleukin 2 receptor, gamma)
(eg, X-linked severe combined immunodeficiency),
full gene sequence ISPD (isoprenoid synthase
domain containing) (eg, muscle-eye-brain disease,
Walker-Warburg syndrome), full gene sequence KRAS
(Kirsten rat sarcoma viral oncogene homolog) (eg,
Noonan syndrome), full gene sequence LAMP2
(lysosomal-associated membrane protein 2) (eg,
Danon disease), full gene sequence LDLR (low
density lipoprotein receptor) (eg, familial
hypercholesterolemia), duplication/deletion
analysis MEN1 (multiple endocrine neoplasia I)
(eg, multiple endocrine neoplasia type 1, Wermer
syndrome), full gene sequence MMAA (methylmalonic
aciduria [cobalamine deficiency] type A) (eg,
MMAA-related methylmalonic acidemia), full gene
sequence MMAB (methylmalonic aciduria [cobalamine
deficiency] type B) (eg, MMAA-related
methylmalonic acidemia), full gene sequence MPI
(mannose phosphate isomerase) (eg, congenital
disorder of glycosylation 1b), full gene sequence
MPV17 (MpV17 mitochondrial inner membrane protein)
(eg, mitochondrial DNA depletion syndrome), full
gene sequence MPZ (myelin protein zero) (eg,
Charcot-Marie-Tooth), full gene sequence MTM1
(myotubularin 1) (eg, X-linked centronuclear
myopathy), duplication/deletion analysis MYL2
(myosin, light chain 2, regulatory, cardiac, slow)
(eg, familial hypertrophic cardiomyopathy), full
gene sequence MYL3 (myosin, light chain 3, alkali,
ventricular, skeletal, slow) (eg, familial
hypertrophic cardiomyopathy), full gene sequence
MYOT (myotilin) (eg, limb-girdle muscular
dystrophy), full gene sequence NDUFS7 (NADH
dehydrogenase [ubiquinone] Fe-S protein 7, 20kDa
[NADH-coenzyme Q reductase]) (eg, Leigh syndrome,
mitochondrial complex I deficiency), full gene
sequence NDUFS8 (NADH dehydrogenase [ubiquinone]
Fe-S protein 8, 23kDa [NADH-coenzyme Q reductase])
(eg, Leigh syndrome, mitochondrial complex I
deficiency), full gene sequence NDUFV1 (NADH
dehydrogenase [ubiquinone] flavoprotein 1, 51kDa)
(eg, Leigh syndrome, mitochondrial complex I
deficiency), full gene sequence NEFL
(neurofilament, light polypeptide) (eg,
Charcot-Marie-Tooth), full gene sequence NF2
(neurofibromin 2 [merlin]) (eg, neurofibromatosis,
type 2), duplication/deletion analysis NLGN3
(neuroligin 3) (eg, autism spectrum disorders),
full gene sequence NLGN4X (neuroligin 4, X-linked)
(eg, autism spectrum disorders), full gene
sequence NPHP1 (nephronophthisis 1 [juvenile])
(eg, Joubert syndrome), deletion analysis, and
duplication analysis, if performed NPHS2
(nephrosis 2, idiopathic, steroid-resistant
[podocin]) (eg, steroid-resistant nephrotic
syndrome), full gene sequence NSD1 (nuclear
receptor binding SET domain protein 1) (eg, Sotos
syndrome), duplication/deletion analysis OTC
(ornithine carbamoyltransferase) (eg, ornithine
transcarbamylase deficiency), full gene sequence
PAFAH1B1 (platelet-activating factor
acetylhydrolase 1b, regulatory subunit 1 [45kDa])
(eg, lissencephaly, Miller-Dieker syndrome),
duplication/deletion analysis PARK2 (Parkinson
protein 2, E3 ubiquitin protein ligase [parkin])
(eg, Parkinson disease), duplication/deletion
analysis PCCA (propionyl CoA carboxylase, alpha
polypeptide) (eg, propionic acidemia, type 1),
duplication/deletion analysis PCDH19
(protocadherin 19) (eg, epileptic encephalopathy),
full gene sequence PDHA1 (pyruvate dehydrogenase
[lipoamide] alpha 1) (eg, lactic acidosis),
duplication/deletion analysis PDHB (pyruvate
dehydrogenase [lipoamide] beta) (eg, lactic
acidosis), full gene sequence PINK1 (PTEN induced
putative kinase 1) (eg, Parkinson disease), full
gene sequence PKLR (pyruvate kinase, liver and
RBC) (eg, pyruvate kinase deficiency), full gene
sequence PLP1 (proteolipid protein 1) (eg,
Pelizaeus-Merzbacher disease, spastic paraplegia),
full gene sequence POU1F1 (POU class 1 homeobox 1)
(eg, combined pituitary hormone deficiency), full
gene sequence PRX (periaxin) (eg,
Charcot-Marie-Tooth disease), full gene sequence
PQBP1 (polyglutamine binding protein 1) (eg,
Renpenning syndrome), full gene sequence PSEN1
(presenilin 1) (eg, Alzheimer disease), full gene
sequence RAB7A (RAB7A, member RAS oncogene family)
(eg, Charcot-Marie-Tooth disease), full gene
sequence RAI1 (retinoic acid induced 1) (eg,
Smith-Magenis syndrome), full gene sequence REEP1
(receptor accessory protein 1) (eg, spastic
paraplegia), full gene sequence RET (ret
proto-oncogene) (eg, multiple endocrine neoplasia,
type 2A and familial medullary thyroid carcinoma),
targeted sequence analysis (eg, exons 10, 11,
13-16) RPS19 (ribosomal protein S19) (eg,
Diamond-Blackfan anemia), full gene sequence RRM2B
(ribonucleotide reductase M2 B [TP53 inducible])
(eg, mitochondrial DNA depletion), full gene
sequence SCO1 (SCO cytochrome oxidase deficient
homolog 1) (eg, mitochondrial respiratory chain
complex IV deficiency), full gene sequence SDHB
(succinate dehydrogenase complex, subunit B, iron
sulfur) (eg, hereditary paraganglioma), full gene
sequence SDHC (succinate dehydrogenase complex,
subunit C, integral membrane protein, 15kDa) (eg,
hereditary paraganglioma-pheochromocytoma
syndrome), full gene sequence SGCA (sarcoglycan,
alpha [50kDa dystrophin-associated glycoprotein])
(eg, limb-girdle muscular dystrophy), full gene
sequence SGCB (sarcoglycan, beta [43kDa
dystrophin-associated glycoprotein]) (eg,
limb-girdle muscular dystrophy), full gene
sequence SGCD (sarcoglycan, delta [35kDa
dystrophin-associated glycoprotein]) (eg,
limb-girdle muscular dystrophy), full gene
sequence SGCE (sarcoglycan, epsilon) (eg,
myoclonic dystonia), duplication/deletion analysis
SGCG (sarcoglycan, gamma [35kDa
dystrophin-associated glycoprotein]) (eg,
limb-girdle muscular dystrophy), full gene
sequence SHOC2 (soc-2 suppressor of clear homolog)
(eg, Noonan-like syndrome with loose anagen hair),
full gene sequence SHOX (short stature homeobox)
(eg, Langer mesomelic dysplasia), full gene
sequence SIL1 (SIL1 homolog, endoplasmic reticulum
chaperone [S. cerevisiae]) (eg, ataxia), full gene
sequence SLC2A1 (solute carrier family 2
[facilitated glucose transporter], member 1) (eg,
glucose transporter type 1 [GLUT 1] deficiency
syndrome), full gene sequence SLC16A2 (solute
carrier family 16, member 2 [thyroid hormone
transporter]) (eg, specific thyroid hormone cell
transporter deficiency, Allan-Herndon-Dudley
syndrome), full gene sequence SLC22A5 (solute
carrier family 22 [organic cation/carnitine
transporter], member 5) (eg, systemic primary
carnitine deficiency), full gene sequence SLC25A20
(solute carrier family 25 [carnitine/acylcarnitine
translocase], member 20) (eg,
carnitine-acylcarnitine translocase deficiency),
full gene sequence SMAD4 (SMAD family member 4)
(eg, hemorrhagic telangiectasia syndrome, juvenile
polyposis), duplication/deletion analysis SPAST
(spastin) (eg, spastic paraplegia),
duplication/deletion analysis SPG7 (spastic
paraplegia 7 [pure and complicated autosomal
recessive]) (eg, spastic paraplegia),
duplication/deletion analysis SPRED1
(sprouty-related, EVH1 domain containing 1) (eg,
Legius syndrome), full gene sequence STAT3 (signal
transducer and activator of transcription 3
[acute-phase response factor]) (eg, autosomal
dominant hyper-IgE syndrome), targeted sequence
analysis (eg, exons 12, 13, 14, 16, 17, 20, 21)
STK11 (serine/threonine kinase 11) (eg,
Peutz-Jeghers syndrome), full gene sequence SURF1
(surfeit 1) (eg, mitochondrial respiratory chain
complex IV deficiency), full gene sequence TARDBP
(TAR DNA binding protein) (eg, amyotrophic lateral
sclerosis), full gene sequence TBX5 (T-box 5) (eg,
Holt-Oram syndrome), full gene sequence TCF4
(transcription factor 4) (eg, Pitt-Hopkins
syndrome), duplication/deletion analysis TGFBR1
(transforming growth factor, beta receptor 1) (eg,
Marfan syndrome), full gene sequence TGFBR2
(transforming growth factor, beta receptor 2) (eg,
Marfan syndrome), full gene sequence THRB (thyroid
hormone receptor, beta) (eg, thyroid hormone
resistance, thyroid hormone beta receptor
deficiency), full gene sequence or targeted
sequence analysis of >5 exons TK2 (thymidine
kinase 2, mitochondrial) (eg, mitochondrial DNA
depletion syndrome), full gene sequence TNNC1
(troponin C type 1 [slow]) (eg, hypertrophic
cardiomyopathy or dilated cardiomyopathy), full
gene sequence TNNI3 (troponin I, type 3 [cardiac])
(eg, familial hypertrophic cardiomyopathy), full
gene sequence TP53 (tumor protein 53) (eg,
Li-Fraumeni syndrome, tumor samples), full gene
sequence or targeted sequence analysis of >5 exons
TPM1 (tropomyosin 1 [alpha]) (eg, familial
hypertrophic cardiomyopathy), full gene sequence
TSC1 (tuberous sclerosis 1) (eg, tuberous
sclerosis), duplication/deletion analysis TYMP
(thymidine phosphorylase) (eg, mitochondrial DNA
depletion syndrome), full gene sequence VWF (von
Willebrand factor) (eg, von Willebrand disease
type 2N), targeted sequence analysis (eg, exons
18-20, 23-25) WT1 (Wilms tumor 1) (eg, Denys-Drash
syndrome, familial Wilms tumor), full gene
sequence ZEB2 (zinc finger E-box binding homeobox
2) (eg, Mowat-Wilson syndrome), full gene sequence
81407 Molecular pathology procedure, Level 8 (eg,
analysis of 26-50 exons by DNA sequence analysis,
mutation scanning or duplication/deletion variants
of >50 exons, sequence analysis of multiple genes
on one platform) ABCC8 (ATP-binding cassette,
sub-family C [CFTR/MRP], member 8) (eg, familial
hyperinsulinism), full gene sequence AGL
(amylo-alpha-1, 6-glucosidase,
4-alpha-glucanotransferase) (eg, glycogen storage
disease type III), full gene sequence AHI1
(Abelson helper integration site 1) (eg, Joubert
syndrome), full gene sequence ASPM (asp [abnormal
spindle] homolog, microcephaly associated
[Drosophila]) (eg, primary microcephaly), full
gene sequence CHD7 (chromodomain helicase DNA
binding protein 7) (eg, CHARGE syndrome), full
gene sequence COL4A4 (collagen, type IV, alpha 4)
(eg, Alport syndrome), full gene sequence COL4A5
(collagen, type IV, alpha 5) (eg, Alport
syndrome), duplication/deletion analysis COL6A1
(collagen, type VI, alpha 1) (eg, collagen type
VI-related disorders), full gene sequence COL6A2
(collagen, type VI, alpha 2) (eg, collagen type
VI-related disorders), full gene sequence COL6A3
(collagen, type VI, alpha 3) (eg, collagen type
VI-related disorders), full gene sequence CREBBP
(CREB binding protein) (eg, Rubinstein-Taybi
syndrome), full gene sequence F8 (coagulation
factor VIII) (eg, hemophilia A), full gene
sequence JAG1 (jagged 1) (eg, Alagille syndrome),
full gene sequence KDM5C (lysine [K]-specific
demethylase 5C) (eg, X-linked mental retardation),
full gene sequence KIAA0196 (KIAA0196) (eg,
spastic paraplegia), full gene sequence L1CAM (L1
cell adhesion molecule) (eg, MASA syndrome,
X-linked hydrocephaly), full gene sequence LAMB2
(laminin, beta 2 [laminin S]) (eg, Pierson
syndrome), full gene sequence MYBPC3 (myosin
binding protein C, cardiac) (eg, familial
hypertrophic cardiomyopathy), full gene sequence
MYH6 (myosin, heavy chain 6, cardiac muscle,
alpha) (eg, familial dilated cardiomyopathy), full
gene sequence MYH7 (myosin, heavy chain 7, cardiac
muscle, beta) (eg, familial hypertrophic
cardiomyopathy, Liang distal myopathy), full gene
sequence MYO7A (myosin VIIA) (eg, Usher syndrome,
type 1), full gene sequence NOTCH1 (notch 1) (eg,
aortic valve disease), full gene sequence NPHS1
(nephrosis 1, congenital, Finnish type [nephrin])
(eg, congenital Finnish nephrosis), full gene
sequence OPA1 (optic atrophy 1) (eg, optic
atrophy), full gene sequence PCDH15
(protocadherin-related 15) (eg, Usher syndrome,
type 1), full gene sequence PKD1 (polycystic
kidney disease 1 [autosomal dominant]) (eg,
polycystic kidney disease), full gene sequence
PLCE1 (phospholipase C, epsilon 1) (eg, nephrotic
syndrome type 3), full gene sequence SCN1A (sodium
channel, voltage-gated, type 1, alpha subunit)
(eg, generalized epilepsy with febrile seizures),
full gene sequence SCN5A (sodium channel,
voltage-gated, type V, alpha subunit) (eg,
familial dilated cardiomyopathy), full gene
sequence SLC12A1 (solute carrier family 12
[sodium/potassium/chloride transporters], member
1) (eg, Bartter syndrome), full gene sequence
SLC12A3 (solute carrier family 12 [sodium/chloride
transporters], member 3) (eg, Gitelman syndrome),
full gene sequence SPG11 (spastic paraplegia 11
[autosomal recessive]) (eg, spastic paraplegia),
full gene sequence SPTBN2 (spectrin, beta,
non-erythrocytic 2) (eg, spinocerebellar ataxia),
full gene sequence TMEM67 (transmembrane protein
67) (eg, Joubert syndrome), full gene sequence
TSC2 (tuberous sclerosis 2) (eg, tuberous
sclerosis), full gene sequence USH1C (Usher
syndrome 1C [autosomal recessive, severe]) (eg,
Usher syndrome, type 1), full gene sequence VPS13B
(vacuolar protein sorting 13 homolog B [yeast])
(eg, Cohen syndrome), duplication/deletion
analysis WDR62 (WD repeat domain 62) (eg, primary
autosomal recessive microcephaly), full gene
sequence
93279 Programming device evaluation (in person) with
iterative adjustment of the implantable device to
test the function of the device and select optimal
permanent programmed values with analysis, review
and report by a physician or other qualified
health care professional; single lead pacemaker
system or leadless pacemaker system in one cardiac
chamber
93285 Programming device evaluation (in person) with
iterative adjustment of the implantable device to
test the function of the device and select optimal
permanent programmed values with analysis, review
and report by a physician or other qualified
health care professional; subcutaneous cardiac
rhythm monitor system
93286 Peri-procedural device evaluation (in person) and
programming of device system parameters before or
after a surgery, procedure, or test with analysis,
review and report by a physician or other
qualified health care professional; single, dual,
or multiple lead pacemaker system, or leadless
pacemaker system
93288 Interrogation device evaluation (in person) with
analysis, review and report by a physician or
other qualified health care professional, includes
connection, recording and disconnection per
patient encounter; single, dual, or multiple lead
pacemaker system, or leadless pacemaker system
93290 Interrogation device evaluation (in person) with
analysis, review and report by a physician or
other qualified health care professional, includes
connection, recording and disconnection per
patient encounter; implantable cardiovascular
physiologic monitor system, including analysis of
1 or more recorded physiologic cardiovascular data
elements from all internal and external sensors
93291 Interrogation device evaluation (in person) with
analysis, review and report by a physician or
other qualified health care professional, includes
connection, recording and disconnection per
patient encounter; subcutaneous cardiac rhythm
monitor system, including heart rhythm derived
data analysis
93294 Interrogation device evaluation(s) (remote), up to
90 days; single, dual, or multiple lead pacemaker
system, or leadless pacemaker system with interim
analysis, review(s) and report(s) by a physician
or other qualified health care professional
93296 Interrogation device evaluation(s) (remote), up to
90 days; single, dual, or multiple lead pacemaker
system, leadless pacemaker system, or implantable
defibrillator system, remote data acquisition(s),
receipt of transmissions and technician review,
technical support and distribution of results
93297 Interrogation device evaluation(s), (remote) up to
30 days; implantable cardiovascular physiologic
monitor system, including analysis of 1 or more
recorded physiologic cardiovascular data elements
from all internal and external sensors, analysis,
review(s) and report(s) by a physician or other
qualified health care professional
93298 Interrogation device evaluation(s), (remote) up to
30 days; subcutaneous cardiac rhythm monitor
system, including analysis of recorded heart
rhythm data, analysis, review(s) and report(s) by
a physician or other qualified health care
professional
93299 Interrogation device evaluation(s), (remote) up to
30 days; implantable cardiovascular physiologic
monitor system or subcutaneous cardiac rhythm
monitor system, remote data acquisition(s),
receipt of transmissions and technician review,
technical support and distribution of results
94780 Car seat/bed testing for airway integrity, for
infants through 12 months of age, with continual
clinical staff observation and continuous
recording of pulse oximetry, heart rate and
respiratory rate, with interpretation and report;
60 minutes
94781 Car seat/bed testing for airway integrity, for
infants through 12 months of age, with continual
clinical staff observation and continuous
recording of pulse oximetry, heart rate and
respiratory rate, with interpretation and report;
each additional full 30 minutes (List separately
in addition to code for primary procedure)
95970 Electronic analysis of implanted neurostimulator
pulse generator/transmitter (eg, contact group[s],
interleaving, amplitude, pulse width, frequency
[Hz], on/off cycling, burst, magnet mode, dose
lockout, patient selectable parameters, responsive
neurostimulation, detection algorithms, closed
loop parameters, and passive parameters) by
physician or other qualified health care
professional; with brain, cranial nerve, spinal
cord, peripheral nerve, or sacral nerve,
neurostimulator pulse generator/transmitter,
without programming
95971 Electronic analysis of implanted neurostimulator
pulse generator/transmitter (eg, contact group[s],
interleaving, amplitude, pulse width, frequency
[Hz], on/off cycling, burst, magnet mode, dose
lockout, patient selectable parameters, responsive
neurostimulation, detection algorithms, closed
loop parameters, and passive parameters) by
physician or other qualified health care
professional; with simple spinal cord or
peripheral nerve (eg, sacral nerve)
neurostimulator pulse generator/transmitter
programming by physician or other qualified health
care professional
95972 Electronic analysis of implanted neurostimulator
pulse generator/transmitter (eg, contact group[s],
interleaving, amplitude, pulse width, frequency
[Hz], on/off cycling, burst, magnet mode, dose
lockout, patient selectable parameters, responsive
neurostimulation, detection algorithms, closed
loop parameters, and passive parameters) by
physician or other qualified health care
professional; with complex spinal cord or
peripheral nerve (eg, sacral nerve)
neurostimulator pulse generator/transmitter
programming by physician or other qualified health
care professional
96116 Neurobehavioral status exam (clinical assessment
of thinking, reasoning and judgment, [eg, acquired
knowledge, attention, language, memory, planning
and problem solving, and visual spatial
abilities]), by physician or other qualified
health care professional, both face-to-face time
with the patient and time interpreting test
results and preparing the report; first hour
99091 Collection and interpretation of physiologic data
(eg, ECG, blood pressure, glucose monitoring)
digitally stored and/or transmitted by the patient
and/or caregiver to the physician or other
qualified health care professional, qualified by
education, training, licensure/regulation (when
applicable) requiring a minimum of 30 minutes of
time, each 30 days
99446 Interprofessional telephone/Internet/electronic
health record assessment and management service
provided by a consultative physician, including a
verbal and written report to the patient’s
treating/requesting physician or other qualified
health care professional; 5-10 minutes of medical
consultative discussion and review
99447 Interprofessional telephone/Internet/electronic
health record assessment and management service
provided by a consultative physician, including a
verbal and written report to the patient’s
treating/requesting physician or other qualified
health care professional; 11-20 minutes of medical
consultative discussion and review
99448 Interprofessional telephone/Internet/electronic
health record assessment and management service
provided by a consultative physician, including a
verbal and written report to the patient’s
treating/requesting physician or other qualified
health care professional; 21-30 minutes of medical
consultative discussion and review
99449 Interprofessional telephone/Internet/electronic
health record assessment and management service
provided by a consultative physician, including a
verbal and written report to the patient’s
treating/requesting physician or other qualified
health care professional; 31 minutes or more of
medical consultative discussion and review
HFAP revised standards: Legionella
To keep themselves as closely aligned with CMS as possible, HFAP has updated their Acute Care Manual with a new requirement for Infection Control Standard 07.01.03—Reduce Risk of Legionella in Water Systems.
Revised ICD codes for the year 2019
For the year 2019, 143 codes have been revised and below is the list of codes with old vs revised descriptions effective for the dates of services from October 1, 2018.
Revised and New Modifiers for Oxygen Flow Rate
To assist in identifying the prescribed flow rate on the claim form, and to ensure appropriate use of modifiers in all cases based on the prescribed flow rate at rest (or at night or based on the average of the rate at rest and at night if applicable) in accordance with Federal regulations, the following three new pricing modifiers are added to the HCPCS file effective April 1, 2018:
1. QA – Prescribed amounts of stationary oxygen for daytime use while at rest and nighttime use differ and the average of the two amounts is less than 1 liter per minute (LPM)
2. QB – Prescribed amounts of stationary oxygen for daytime used while at rest and nighttime use differ and the average of the two amounts exceeds 4 liters per minute (LPM) and portable oxygen is prescribed
3. QR – Prescribed amounts of stationary oxygen for daytime use while at rest and nighttime use differ and the average of the two amounts is greater than 4 liters per minute (LPM)
Additionally, the existing QE, QF, and QG modifiers are revised to clarify that the prescribed flow rate at rest is used in accordance with regulations at 42 CFR 414.226(e)(3). This section instructs that if the prescribed flow rate is different for the patient at rest than for the patient at exercise, the flow rate for the patient at rest is used.
Effective April 1, 2018, these modifiers are revised to read:
1. QE – Prescribed amount of stationary oxygen while at rest is less than 1 liter per minute (LPM)
2. QF – Prescribed amount of stationary oxygen while at rest exceeds 4 liters per minute (LPM) and portable oxygen is prescribed
3. QG – Prescribed amount of stationary oxygen while at rest is greater than 4 liters per minute (LPM)
For more information: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM10158.pdf